Results 11 to 20 of about 79,311 (270)
Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer [PDF]
, 2010 We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients.
Akashi, Isao +13 more
core +1 more source
Pharmacogenomics, 2010 Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is ...
Sharon, Marsh, Janelle M, Hoskins
openaire +3 more sources
PLoS ONE, 2020 Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka +11 more
doaj +1 more source
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response [PDF]
, 2016 Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly because of cancer recurrence and metastasis.
Biffoni, Mauro +9 more
core +1 more source
BMC Microbiology, 2023 Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy +7 more
doaj +1 more source
PLoS ONE, 2015 Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi +4 more
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with ...
Jiaojiao Suo +12 more
doaj +1 more source
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]
, 2013 Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO +15 more
core +1 more source
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) [PDF]
, 2012 The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and tumour response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of metastatic ...
Eichler, Katrin +6 more
core +1 more source
Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer [PDF]
, 2010 We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Fujimoto, Nobukazu +8 more
core +1 more source